Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Losartan: lessons learned from the RENAAL study.

Shahnaz Shahinfar1, Paulette A Lyle, Zhongxin Zhang

  • 1Merck & Co., Inc., Whitehouse Station, New Jersey, USA.

Expert Opinion on Pharmacotherapy
|March 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of two QTLs and development of KASP molecular markers for seed coat cracking tolerance in peanut (<i>Arachis hypogaea</i> L.).

Molecular breeding : new strategies in plant improvement·2026
Same author

Fast High-Order Consensus Time Synchronization Protocol in Industrial Wireless Sensor Networks.

Sensors (Basel, Switzerland)·2026
Same author

Development and applications of A-genome chromosome-specific oligo pools for peanut genomic relationships revealing and single-chromosome microdissection.

The Plant journal : for cell and molecular biology·2026
Same author

Quantifying the Heterogeneity of TRUS-Visible Lesions for Predicting Prostate Cancer: A Multicenter Preliminary Study.

Academic radiology·2026
Same author

Deciphering and harnessing promoter-driven feedback controllers to mitigate metabolic burden in Corynebacterium glutamicum.

Trends in biotechnology·2026
Same author

Origin of small chromosome A08 and genome evolution of Arachis species.

Nature communications·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

The RENAAL study found that losartan significantly reduced renal and cardiovascular events in patients with Type 2 diabetes and nephropathy. This landmark trial offers valuable insights for future clinical research in this high-risk population.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Type 2 diabetes is a growing global health concern.
  • Diabetic nephropathy and cardiovascular disease are major complications.
  • These conditions pose significant burdens on patients and healthcare systems.

Purpose of the Study:

  • To review key findings from the RENAAL study.
  • To analyze renal and cardiovascular outcomes in Type 2 diabetes patients with nephropathy.
  • To identify risk predictors for these complications.

Main Methods:

  • The RENAAL study (1996-2001) involved a large cohort of patients.
  • It focused on patients with Type 2 diabetes and nephropathy.
  • The study evaluated the effects of losartan, an angiotensin II antagonist.

Related Experiment Videos

Main Results:

  • Losartan demonstrated significant reductions in renal and cardiovascular endpoints.
  • Key risk predictors for adverse outcomes were identified.
  • The study provided valuable data for clinical trial design.

Conclusions:

  • Losartan is effective in managing renal and cardiovascular risks in Type 2 diabetes with nephropathy.
  • The RENAAL study significantly advanced understanding of managing these complications.
  • Findings inform future clinical trials and patient management strategies.